Vireo Growth (VREOF) Non-Current Assets (2020 - 2026)
Vireo Growth (VREOF) reported Non-Current Assets of $670.5 million for Q1 2026, up 1279.27% on a YoY basis from $48.6 million in Q1 2025, and up 30.93% sequentially from $512.1 million in Q4 2025.
Vireo Growth (VREOF) Non-Current Assets (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Non-Current Assets data on file, last reported at $670.5 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets rose 1279.27% year-over-year to $670.5 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 billion (up 884.23% YoY), and the FY2025 full-year result was $512.1 million, up 956.06% from the prior year.
- Non-Current Assets improved to $670.5 million in Q1 2026, from $512.1 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $670.5 million in Q1 2026 to a low of $34.4 million in Q4 2023.
- A 5-year average of $162.8 million and a median of $49.9 million in 2024 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets sank 69.4% in 2023 and soared 1279.27% in 2026, its largest moves.
- Tracing VREOF's Non-Current Assets over 5 years: stood at $112.4 million in 2022, then slumped by 69.39% to $34.4 million in 2023, then surged by 40.92% to $48.5 million in 2024, then surged by 956.06% to $512.1 million in 2025, then jumped by 30.93% to $670.5 million in 2026.
- Business Quant data shows VREOF's Non-Current Assets at $670.5 million in Q1 2026, $512.1 million in Q4 2025, and $371.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 670.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 670.50 Mn |
| Dec 31, 2025 | 512.10 Mn |
| Sep 30, 2025 | 370.95 Mn |
| Jun 30, 2025 | 346.55 Mn |
| Mar 31, 2025 | 48.61 Mn |
| Dec 31, 2024 | 48.49 Mn |
| Sep 30, 2024 | 49.90 Mn |
| Jun 30, 2024 | 46.05 Mn |
| Mar 31, 2024 | 43.71 Mn |
| Dec 31, 2023 | 34.41 Mn |
| Sep 30, 2023 | 36.56 Mn |
| Jun 30, 2023 | 39.58 Mn |
| Mar 31, 2023 | 43.08 Mn |
| Dec 31, 2022 | 112.43 Mn |
| Sep 30, 2022 | 119.46 Mn |
| Jun 30, 2022 | 122.43 Mn |
| Mar 31, 2022 | 121.98 Mn |
| Dec 31, 2021 | 125.33 Mn |
| Sep 30, 2021 | 119.41 Mn |
| Jun 30, 2021 | 70.71 Mn |